Literature DB >> 23339067

Hepatocyte caspase-8 is an essential modulator of steatohepatitis in rodents.

Maximilian Hatting1, Gang Zhao, Fabienne Schumacher, Gernot Sellge, Malika Al Masaoudi, Nikolaus Gaβler, Mark Boekschoten, Michael Müller, Christian Liedtke, Francisco Javier Cubero, Christian Trautwein.   

Abstract

UNLABELLED: In human and murine models of nonalcoholic steatohepatitis (NASH), increased hepatocyte apoptosis is a critical mechanism contributing to inflammation and fibrogenesis. Caspase 8 (Casp8) is essential for death-receptor-mediated apoptosis activity and therefore its modulation might be critical for the pathogenesis of NASH. The aim was to dissect the role of hepatocyte Casp8 in a murine model of steatohepatitis. We generated hepatocyte-specific Casp8 knockout (Casp8(Δhep) ) mice. Animals were fed with a methionine-choline-deficient (MCD) diet. Liver injury was assessed by histopathological analysis, apoptotic death, serum alanine aminotransferase (ALT), fluorescent-activated cell sorter (FACS), analysis of liver infiltration and inflammation, reactive oxygen species (ROS), and liver fibrosis. MCD feeding triggered steatosis, hepatic lipid storage, and accumulation of free fatty acid (FFA) in wildtype (WT) livers, which were significantly reduced in Casp8(Δhep) animals. Additionally, lack of Casp8 expression in hepatocytes reduced the MCD-dependent increase in apoptosis and decreased expression of proinflammatory cytokines as well as hepatic infiltration. As a consequence, ROS production was lower, leading to a reduction in the progression of liver fibrosis in Casp8(Δhep) livers.
CONCLUSION: Selective ablation of Casp8 in hepatocytes ameliorates development of NASH by modulating liver injury. Casp8-directed therapy might be a plausible treatment for patients with steatohepatitis. (HEPATOLOGY 2013;57:2189-2201).
Copyright © 2013 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23339067     DOI: 10.1002/hep.26271

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  39 in total

1.  Upregulation of BCL-2 by acridone derivative through gene promoter i-motif for alleviating liver damage of NAFLD/NASH.

Authors:  Xiaoya Li; Jing Wang; Xue Gong; Meiling Zhang; Shuangshuang Kang; Bing Shu; Zuzhuang Wei; Zhi-Shu Huang; Ding Li
Journal:  Nucleic Acids Res       Date:  2020-09-04       Impact factor: 16.971

2.  Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity.

Authors:  Yong Rao; Yu-Ting Lu; Chan Li; Qin-Qin Song; Yao-Hao Xu; Zhao Xu; Yu-Tao Hu; Hong Yu; Lin Gao; Lian-Quan Gu; Ji-Ming Ye; Zhi-Shu Huang
Journal:  Br J Pharmacol       Date:  2019-07-04       Impact factor: 8.739

3.  Mechanism of the promotion of steatotic HepG2 cell apoptosis by cholesterol.

Authors:  Chunyan Zhu; Ping Xie; Fei Zhao; Lingqiang Zhang; Wei An; Yutao Zhan
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

4.  Ectopic localization of autophagosome in fatty liver is a key factor for liver regeneration.

Authors:  Yoshihiro Matsumoto; Tomoharu Yoshizumi; Takeo Toshima; Kazuki Takeishi; Takasuke Fukuhara; Shinji Itoh; Toru Ikegami; Yuji Soejima; Masaki Mori
Journal:  Organogenesis       Date:  2019-07-06       Impact factor: 2.500

Review 5.  Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis.

Authors:  Thomas Greuter; Harmeet Malhi; Gregory J Gores; Vijay H Shah
Journal:  JCI Insight       Date:  2017-09-07

6.  Caspase 3 inactivation protects against hepatic cell death and ameliorates fibrogenesis in a diet-induced NASH model.

Authors:  Samjhana Thapaliya; Alexander Wree; Davide Povero; Maria Eugenia Inzaugarat; Michael Berk; Laura Dixon; Bettina G Papouchado; Ariel E Feldstein
Journal:  Dig Dis Sci       Date:  2014-05-03       Impact factor: 3.199

7.  TRAIL receptor deletion in mice suppresses the inflammation of nutrient excess.

Authors:  Leila Idrissova; Harmeet Malhi; Nathan W Werneburg; Nathan K LeBrasseur; Steven F Bronk; Christian Fingas; Tamar Tchkonia; Tamar Pirtskhalava; Thomas A White; Michael B Stout; Petra Hirsova; Anuradha Krishnan; Christian Liedtke; Christian Trautwein; Niklas Finnberg; Wafik S El-Deiry; James L Kirkland; Gregory J Gores
Journal:  J Hepatol       Date:  2014-11-28       Impact factor: 25.083

Review 8.  Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.

Authors:  Alessandro Federico; Claudio Zulli; Ilario de Sio; Anna Del Prete; Marcello Dallio; Mario Masarone; Carmela Loguercio
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

Review 9.  Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.

Authors:  Giovanni Musso; Maurizio Cassader; Roberto Gambino
Journal:  Nat Rev Drug Discov       Date:  2016-01-22       Impact factor: 84.694

Review 10.  RIP3: a molecular switch for necrosis and inflammation.

Authors:  Kenta Moriwaki; Francis Ka-Ming Chan
Journal:  Genes Dev       Date:  2013-08-01       Impact factor: 11.361

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.